肺肉瘤样癌治疗的研究进展  

Research progress in the treatment of pulmonary sarcomatoid carcinoma

作　　者：焦小玲 孙荣丽 张京乙 刘凤娟 JIAO Xiaoling;SUN Rongli;ZHANG Jingyi;LIU Fengjuan(School of Clinical Medicine,Shandong Second Medical University,Weifang,Shandong 261000,China;Department of Respiratory and Critical Care Medicine,Qingdao Central Hospital,Qingdao,Shandong 266000,China;School of Medicine and Pharmacy,Ocean University of China,Qingdao,Shandong 266003,China;Clinical Trial Research Center of Qingdao Central Hospital,University of Health and Rehabilitation Sciences,Qingdao,Shandong 266000,China)

机构地区：[1]山东第二医科大学临床医学院,山东潍坊261000 [2]青岛市中心医院呼吸与危重症医学科,山东青岛266000 [3]中国海洋大学医药学院,山东青岛266003 [4]康复大学青岛中心医院临床试验研究中心,山东青岛266000

出　　处：《重庆医学》2025年第4期1005-1009,共5页Chongqing Medical Journal

基　　金：山东省青岛市2023年度医药卫生科研指导项目(2023-WJZD225)。

摘　　要：肺肉瘤样癌(PSC)是一组罕见的非小细胞肺癌,具有强侵袭性,易发生转移和复发,预后极差,通常发现时多处于晚期,错失手术时机,并对放、化疗不敏感。研究发现PSC的程序性死亡受体-1/程序性死亡受体-配体1高水平表达且大多数存在基因突变。中药具有多靶点、不良反应小、疗效好的特点,广泛应用于各种恶性肿瘤的临床治疗中,显示出良好的抗肿瘤效果。近年来,免疫治疗和靶向治疗在抗肿瘤领域取得里程碑式突破,基于此,该文旨在综述PSC的治疗方法,为治疗此类具有高恶性程度及不良预后的疾病提供新的研究方向及依据。Pulmonary sarcomatoid carcinoma(PSC)is a group of rare non-small cell lung cancers that are highly aggressive,prone to metastasis and recurrence and have poor prognosis.They are usually diagnosed at an advanced stage,when surgery is no longer an option,and are unresponsive to radiotherapy and chemotherapy.The research found that PSC’s programmed death receptor-1/programmed death receptor-ligand 1 was highly expressed and most of them had genetic mutations.Chinese medicines are widely used in clinical treatment for various malignant tumors due to their multi-targeting characteristics,low side effects,and good efficacy,demonstrating significant anti-tumor effects.Given the breakthrough success of immunotherapy and targeted therapy in recent years,the article promises to provide new ideas and targets for treating this highly malignant disease with a poor prognosis.

关 键 词：肺肉瘤样癌 非小细胞肺癌 程序性死亡受体-1 程序性死亡受体-配体1 

分 类 号：R734.2[医药卫生—肿瘤]